

When requesting Jetrea® (ocriplasmin), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines and applicable safety criteria for the covered indications.

FDA-approved indication

- For the treatment of symptomatic vitreomacular adhesion.

Coverage Guidelines

Symptomatic Vitreomacular Adhesion

The individual must meet all of the following criteria for approval:

- Diagnosis of symptomatic vitreomacular adhesion
- ≥18 years of age
- No repeat administration of Jetrea® (ocriplasmin) in the same eye
- If the contralateral eye requires treatment, Jetrea® (ocriplasmin) is not recommended within 7 days of the initial injection

Approval duration: One dose

Dosing Recommendations

- 0.125mg administered via intravitreal injection, once. It is not recommended to treat the other eye within 7 days of initial injection.

References

1. Jetrea® prescribing information. Iselin, NJ: ThromboGenics, Inc.: February 2017.
2. Ocriplasmin (Jetrea®). In DRUGDEX® System Micromedex 2.0. Greenwood Village, CO: Thompson Reuters (Healthcare) Inc. [Accessed April 17, 2018].
3. Neffendork JE et al. Ocriplasmin for symptomatic vitreomacular adhesion. Cochrane Review October, 17, 2017.
4. Stalmans P et al. Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes. *NEJM* 2012;367:606-615.
5. American Academy of Ophthalmology Preferred Practice Pattern Idiopathic Macular Hole (2017).